Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin

Urology

Volumn 76, Issue 5, 2010, Pages 1240-1244

  Patel, Trushar ^a   Hruby, Greg ^a   Badani, Ketan ^a   Abate Shen, Cory ^a   McKiernan, James M ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; ETHNICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

AGED; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 78149357382     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.03.059     Document Type: Article

References (33)

1. S. Bonovas, K. Filioussi, and A. Tsantes Diabetes mellitus and risk of prostate cancer: a meta-analysis Diabetologia 47 2004 1071 1078
2. J.S. Kasper, and E. Giovannucci A meta-analysis of diabetes mellitus and the risk of prostate cancer Cancer Epidemiol Biomarkers Prev 15 2006 2056 2062
3. C. Polychronakos, U. Janthly, J.G. Lehoux, and M. Koutsilieris Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved Prostate 19 1991 313 321
4. A.W. Hsing, S. Chua Jr., Y.T. Gao, E. Gentzschein, L. Chang, J. Deng, and F.Z. Stanczyk Prostate cancer risk and serum levels of insulin and leptin: a population-based study J Natl Cancer Inst 93 2001 783 789
5. S. Lehrer, E.J. Diamond, S. Stagger, N.N. Stone, and R.G. Stock Increased serum insulin associated with increased risk of prostate cancer recurrence Prostate 50 2002 1 3
6. M. Iwamura, P.M. Sluss, J.B. Casamento, and A.T. Cockett Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines Prostate 22 1993 243 252
7. J.M. Chan, M.J. Stampfer, and E. Giovannucci Plasma insulin-like growth factor I and prostate cancer risk: a prospective study Science 279 1998 563 566
8. P. Stattin, A. Bylund, and S. Rinaldi Plasma insulin-like growth factor I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study J Natl Cancer Inst 92 2000 1910 1917
9. J.S. Kasper, Y. Liu, and E. Giovannucci Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study Int J Cancer 124 2009 1398 1403
10. R.S. Hundal, M. Krssak, and S. Dufour Mechanism by which metformin reduces glucose production in type 2 diabetes Diabetes 49 2000 2063 2069
11. M. Stumvoll, N. Nurjhan, G. Perriello, G. Dailey, and J.E. Gerich Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N Engl J Med 333 1995 550 554
12. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
13. S.L. Bowker, S.R. Majumdar, P. Veugelers, and J.A. Johnson Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 2006 254 258
14. A. Vazquez-Martin, C. Oliveras-Ferraros, and J.A. Menendez The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells Cell Cycle 8 2009 88 96
15. Y. Zhuang, and W.K. Miskimins Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 J Mol Signal 3 2008 18
16. M. Buzzai, R.G. Jones, R.K. Amaravadi, J.J. Lum, R.J. DeBerardinis, F. Zhao, B. Viollet, and C.B. Thompson Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res 67 2007 6745 6752
17. I. Ben Sahra, K. Laurent, and A. Loubat The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 27 2008 3576 3586
18. R.J. Dowling, M. Zakikhani, I.G. Fantus, M. Pollak, and N. Sonenberg Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
19. M.B. Schneider, H. Matsuzaki, and J. Haorah Prevention of pancreatic cancer induction in hamsters by metformin Gastroenterology 120 2001 1263 1270
20. M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, and M. Pollak Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 2006 10269 10273
21. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Del Barco, B. Martin-Castillo, and J.A. Menendez mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) Clin Transl Oncol 11 2009 455 459
22. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 2009 1617 1622
23. M.W. Kattan, J.A. Eastham, A.M. Stapleton, T.M. Wheeler, and P.T. Scardino A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
24. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
25. C.W. Kinkade, M. Castillo-Martin, and A. Puzio-Kuter Targeting Akt/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 2008 3051 3064
26. A. Carracedo, L. Ma, and J. Teruya-Feldstein Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065 3074
27. J.M. Chan, D.M. Latini, J. Cowan, J. Duchane, and P.R. Carroll History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States) Cancer Causes Control 16 2005 789 797
28. J. Jayachandran, W.J. Aronson, M.K. Terris, J.C. Presti Jr., C.L. Amling, C.J. Kane, and S.J. Freedland Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database Cancer Epidemiol Biomarkers Prev 19 2010 9 17
29. R.J. Hamilton, W.J. Aronson, J.C. Presti Jr., M.K. Terris, C.J. Kane, C.L. Amling, and S.J. Freedland Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database Cancer 110 2007 2202 2209
30. J.W. Moul, R.R. Connelly, and D.P. Lubeck Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases J Urol 166 2001 1322 1327
31. S.J. Freedland, C.L. Amling, F. Dorey, C.J. Kane, J.C. Presti Jr., M.K. Terris, and W.J. Aronson Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database Urology 60 2002 670 674
32. J.A. Antonelli, L.W. Jones, and L.L. Banez Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy J Urol 182 2009 2226 2231
33. S.S. Strom, Y. Yamamura, M.R. Forman, C.A. Pettaway, S.L. Barrera, and J. DiGiovanni Saturated fat intake predicts biochemical failure after prostatectomy Int J Cancer 122 2008 2581 2585